We serve Chemical Name:2-Chloromethylbenzimidazole CAS:4857-04-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Chloromethylbenzimidazole
CAS.NO:4857-04-9
Synonyms:2-(Chloromethyl)benzimidazole;EINECS 225-452-8;MFCD00005602;2-(chloromethyl)-1H-benzimidazole
Molecular Formula:C8H7ClN2
Molecular Weight:166.60800
HS Code:2933990090
Physical and Chemical Properties:
Melting point:146-148 °C (dec.)(lit.)
Boiling point:371ºC at 760 mmHg
Density:1.356g/cm3
Index of Refraction:1.679
PSA:28.68000
Exact Mass:166.03000
LogP:2.30170
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 2-(Chloromethyl)benzimidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(chloromethyl)-1H-benzimidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 225-452-8 Use and application,MFCD00005602 technical grade,usp/ep/jp grade.
Related News: It is foreseeable that in the future, the capacity and output of bulk APIs in China will decrease, the supply-demand relationship will be balanced, and prices and profits will gradually return to a more reasonable range. The era of low prices in the past will be gone forever. Individual APIs Varieties may even lose their price competitive advantage and move abroad. 2-Chloromethylbenzimidazole manufacturer Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high. 2-Chloromethylbenzimidazole supplier Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. 2-Chloromethylbenzimidazole vendor Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. 2-Chloromethylbenzimidazole factory Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study.
